Prescription Drugs Market Report 2026

The prescription drugs market size has grown rapidly in recent years. It will grow from $1.43 trillion in 2025 to $1.58 trillion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to expansion of pharmaceutical manufacturing capacity, rising prevalence of chronic diseases, growth of branded drug portfolios, increasing healthcare expenditure, expansion of hospital-based drug dispensing.

The prescription drugs market size is expected to see rapid growth in the next few years. It will grow to $2.36 trillion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing demand for cost-effective generics, rising adoption of biosimilars, expansion of digital prescription platforms, growing focus on personalized drug therapies, increasing regulatory harmonization across markets. Major trends in the forecast period include increasing adoption of specialty prescription drugs, rising demand for generic drug alternatives, growing focus on chronic disease management, expansion of biologic and biosimilar therapies, enhanced regulatory oversight of drug safety.

The growing production of drugs is expected to drive the growth of the prescription drug market in the coming years. Drug production involves the organized process of creating pharmaceutical products, including their formulation, testing, and packaging, to ensure quality, safety, and effectiveness. Increasing drug production is essential to meet the rising global demand for medications, address public health challenges, and ensure the timely availability of treatments for various medical conditions. Enhanced drug production can improve the availability, affordability, and innovation in the prescription drug market, ultimately benefiting patients and the healthcare system by improving access to essential medications and supporting better health outcomes. For example, in October 2025, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based organization representing the pharmaceutical sector, reported significant growth in the European pharmaceutical industry, with production rising from $438 billion (€405.7 billion) in 2023 to $475 billion (€440 billion) in 2024. Therefore, the increase in drug production will drive the development of the prescription drug market.

Leading companies in the prescription drug market are developing alternatives to Victoza (liraglutide) or similar GLP-1 receptor agonist therapies to offer improved options for managing type 2 diabetes. Victoza is a brand-name prescription medication containing liraglutide, a GLP-1 receptor agonist, primarily used to manage type 2 diabetes in adults and children aged 10 years and older. For example, in June 2024, Teva Pharmaceuticals, an Israel-based company, launched an authorized generic of Victoza (liraglutide injection 1.8 mg), providing a more affordable alternative while maintaining the same formulation, efficacy, and quality as the original branded product. This launch aims to improve access to essential diabetes treatments, offering cost-effective options for managing type 2 diabetes and reducing cardiovascular risks associated with the condition.

In December 2023, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. With this acquisition, Bristol Myers Squibb aims to strengthen its neuroscience portfolio by integrating Karuna’s novel cholinergic-based therapies, including KarXT, and expanding its pipeline of treatments for schizophrenia and Alzheimer’s disease psychosis. Karuna Therapeutics is a US-based biopharmaceutical company focused on developing prescription drugs for neuroscience disorders.

Major companies operating in the prescription drugs market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Allergan plc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited.

North America was the largest region in the prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prescription drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prescription drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the prescription drugs market by increasing costs of imported active pharmaceutical ingredients, excipients, packaging materials, and manufacturing equipment used in branded and generic drug production. Pharmaceutical manufacturers and hospitals in North America and Europe are most affected due to globalized supply chains, while Asia-Pacific faces export-related pricing pressure. These tariffs are increasing production costs and affecting drug pricing structures. However, they are also promoting domestic API manufacturing, regional supply chain diversification, and increased investment in local pharmaceutical production facilities.

The prescription drugs market research report is one of a series of new reports that provides prescription drugs market statistics, including prescription drugs industry global market size, regional shares, competitors with a prescription drugs market share, detailed prescription drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prescription drugs industry. This prescription drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prescription drugs are medications that can only be legally obtained with a valid prescription from a licensed healthcare provider. These drugs are used to treat, manage, or prevent various medical conditions, and are prescribed and monitored by healthcare professionals to ensure proper use and minimize the risk of misuse or adverse effects.

Prescription drugs are mainly categorized into branded and generic types. Branded prescription drugs are medications marketed under a proprietary, trademarked name given by the pharmaceutical company that develops and patents the drug. The routes of administration for these drugs include oral, topical, parenteral, and others, and they are used in therapy areas such as oncology, immunology, ophthalmology, respiratory, dermatology, gastroenterology, urology, gynecology, endocrinology, and more. End users of prescription drugs include hospitals, specialty clinics, homecare, and others.

The prescription drugs market consists of sales of bronchodilators, corticosteroids, combination inhalers, antibiotics, mucolytics, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.